Tissue Regenix Group PLC Confirmation of Interim Results (6310V)

TIDMTRX

RNS Number : 6310V

Tissue Regenix Group PLC

11 August 2022

Tissue Regenix Group plc

("Tissue Regenix" or the "Group")

Confirmation of Interim Results

Investor Presentation

Tissue Regenix (AIM: TRX), the regenerative medical devices company, confirms it will issue its interim results for the six months ended 30 June 2022 on Wednesday 7 September 2022.

Investor Briefing

Daniel Lee, Chief Executive Officer, and David Cocke, Chief Financial Officer, will be hosting a live online presentation relating to the interim results via the Investor Meet Company platform at 4.30pm on Wednesday 7 September 2022. The presentation is open to all existing and potential shareholders.

Investors can sign up to Investor Meet Company for free and register for the presentation here: https://www.investormeetcompany.com/tissue-regenix-group-plc/register-investor

Investors who already follow Tissue Regenix on the Investor Meet Company platform will automatically be invited.

For more information:

 
 Tissue Regenix Group plc                            www.tissueregenix.com 
  David Cocke, Chief Financial Officer                     Via Walbrook PR 
 
 Stifel Nicolaus Europe Limited (Nominated         Tel: +44(0)20 7710 7600 
  Adviser and Broker) 
  Ben Maddison / Nicholas Harland 
 Walbrook PR Ltd                                  Tel: +44 (0)20 7933 8780 
  Alice Woodings / Lianne Applegarth          TissueRegenix@walbrookpr.com

About Tissue Regenix (www.tissuergenix.com)

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL(R)') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.

In August 2017 Tissue Regenix acquired CellRight Technologies(R), a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopaedic, foot & ankle, dental, and sports medicine surgical procedures.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORURAWRUNUWAAR

(END) Dow Jones Newswires

August 11, 2022 02:00 ET (06:00 GMT)

Tissue Regenix (LSE:TRX)
Historical Stock Chart
From May 2024 to Jun 2024